This company listing is no longer active
Conformis (CFMS) Stock Overview
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CFMS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Conformis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.26 |
| 52 Week High | US$7.25 |
| 52 Week Low | US$1.05 |
| Beta | 1.39 |
| 1 Month Change | 0.44% |
| 3 Month Change | 96.52% |
| 1 Year Change | -65.23% |
| 3 Year Change | -87.44% |
| 5 Year Change | -91.93% |
| Change since IPO | -99.53% |
Recent News & Updates
Recent updates
Conformis stock jumps 17% aftermarket on FDA 510(k) clearance for Actera hip system
Sep 13Conformis signs agreement with Vizient for personalized orthopedic implants
Aug 01Investors Will Want Conformis' (NASDAQ:CFMS) Growth In ROCE To Persist
Jan 11
We Think Conformis (NASDAQ:CFMS) Can Stay On Top Of Its Debt
Dec 21What Does Conformis, Inc.'s (NASDAQ:CFMS) Share Price Indicate?
Nov 11Is Conformis (NASDAQ:CFMS) A Risky Investment?
Sep 16Conformis: Emerging Surgical Implant Developer
Sep 04Shareholders Shouldn’t Be Too Comfortable With Conformis' (NASDAQ:CFMS) Strong Earnings
Aug 11Party Time: Brokers Just Made Major Increases To Their Conformis, Inc. (NASDAQ:CFMS) Earnings Forecasts
Aug 10Increases to Conformis, Inc.'s (NASDAQ:CFMS) CEO Compensation Might Cool off for now
May 18Analysts Just Shipped An Incredible Upgrade To Their Conformis, Inc. (NASDAQ:CFMS) Estimates
May 11Is Conformis (NASDAQ:CFMS) Using Debt Sensibly?
May 08Is Conformis (NASDAQ:CFMS) Using Too Much Debt?
Jan 16Shareholder Returns
| CFMS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 1.7% |
| 1Y | -65.2% | -3.1% | 14.5% |
Return vs Industry: CFMS underperformed the US Medical Equipment industry which returned 3.9% over the past year.
Return vs Market: CFMS underperformed the US Market which returned 11.1% over the past year.
Price Volatility
| CFMS volatility | |
|---|---|
| CFMS Average Weekly Movement | 25.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CFMS's share price has been volatile over the past 3 months.
Volatility Over Time: CFMS's weekly volatility has increased from 20% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 295 | Mark Augusti | www.conformis.com |
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation.
Conformis, Inc. Fundamentals Summary
| CFMS fundamental statistics | |
|---|---|
| Market cap | US$17.80m |
| Earnings (TTM) | -US$41.50m |
| Revenue (TTM) | US$57.06m |
Is CFMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CFMS income statement (TTM) | |
|---|---|
| Revenue | US$57.06m |
| Cost of Revenue | US$38.12m |
| Gross Profit | US$18.95m |
| Other Expenses | US$60.45m |
| Earnings | -US$41.50m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.27 |
| Gross Margin | 33.21% |
| Net Profit Margin | -72.73% |
| Debt/Equity Ratio | 64.4% |
How did CFMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/06 16:37 |
| End of Day Share Price | 2023/09/01 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Conformis, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Michael Gorman | BTIG |
| Kyle Rose | Canaccord Genuity |